Glioblastoma Multiforme Market

LAS VEGAS, NEVADA, UNITED STATES, April 2, 2024 /EINPresswire.com/ -- DelveInsight’s ‘Glioblastoma Multiforme Market Insights, Epidemiology and Market Forecast– 2032’ report delivers an in-depth understanding of the Glioblastoma Multiforme, historical and forecasted epidemiology as well as the Glioblastoma Multiforme market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Key Takeaways from the Glioblastoma Multiforme Market Report
• As per DelveInsight’s analysis, Japan had 1,950 diagnosed incident cases of Glioblastoma Multiforme in 2020.
• The total diagnosed incident population of Glioblastoma Multiforme in the 7 major markets was estimated to be 29,440 in 2020. In case of Glioblastoma Multiforme patients in the United States, the diagnosed incident cases were 15,426 in 2020.
• The leading Glioblastoma Multiforme Companies working in the market include Genentech, Merck, Daiichi Sankyo, VBL Therapeutics, Diffusion Pharmaceuticals Bayer, MedImmune, DNAtrix, Chimerix, Karyopharm Therapeutics, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, Treovir, Istari Oncology, and others.
• Promising Glioblastoma Multiforme Pipeline Therapies in the various stages of development include Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, LAM561 (2-OHOA), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, VAL-083 (dianhydrogalactitol), MDNA55, Paxalisib (GDC-0084), Temferon, EO2401, INO-5401 + INO-9012 + LIBTAYO (cemiplimab), Delytact (Teserpaturev/DS-1647), TAFINLAR + MEKINIST, VBI-1901, and others.
• March 2024: Laminar Pharmaceuticals announced a study of Phase 2 clinical trials for LAM561 and TMZ. The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with standard of care (SoC) therapy of radiation therapy plus temozolomide (TMZ), followed by an adjuvant treatment of 6 month period of TMZ and then LAM561 or placebo in monotherapy.
• March 2024: TVAX Biomedical announced a study of Phase 2 & 3 clinical trials for Temozolomide. This randomized study is designed to compare the combination of TVI-Brain-1 immunotherapy and standard therapy compared to standard therapy alone as a treatment for newly diagnosed MGMT unmethylated glioblastoma patients. The patients' own cancer cells collected after surgery are combined into a vaccine to produce an immune response that significantly increases the number of cancer neoantigen-specific effector T cell precursors in the patient's body.

Discover which therapies are expected to grab the Glioblastoma Multiforme Market Share @ Glioblastoma Multiforme Market Outlook

Glioblastoma Multiforme Overview
Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumor of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that innovative diagnostic strategies and new therapies have been developed. GBMs can be classified into primary and secondary GBMs. Primary GBM occurs de novo without evidence of a less malignant precursor while Secondary GBM develops from initially low-grade diffuse astrocytoma (WHO grade II diffuse astrocytoma) or anaplastic astrocytoma (Grade III).

Glioblastoma Multiforme Epidemiology Segmentation in the 7MM
• Total Diagnosed Incident Population
• Gender-specific Diagnosed Incidence
• Type-specific Diagnosed Incidence
• Age-specific Diagnosed Incidence
• Diagnosed Incident Population based on Primary Site
• Diagnosed Incident Population based on Histologic Classification of Glioblastoma Tumor

Download the report to understand which factors are driving Glioblastoma Multiforme Epidemiology trends @ Glioblastoma Multiforme Epidemiological Insights

Glioblastoma Multiforme Treatment Market
Glioblastoma multiforme is typically treated with a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Although rarely used alone, surgery is usually one of the most important aspects of glioblastoma treatment. Because glioblastomas grow so quickly, they are frequently difficult to remove completely. As a result, surgery is performed to achieve the best possible safe resection - removing as much of the tumor as possible while preserving brain function and sparing healthy tissues. Following surgery, residual cancer cells can be targeted with additional treatments such as chemotherapy or radiation therapy. Once the tumor's diagnosis or name is determined, radiation therapy and chemotherapy are usually administered.

Glioblastoma Multiforme Market Dynamics
The Glioblastoma Multiforme Market Dynamics is predicted to change in the coming years owing to the improvement in the research and development activities so that glioblastoma multiforme market will comprise of efficient glioblastoma treatment options. Moreover, the anticipated launch of emerging therapies during the forecast period is further expected to fuel the glioblastoma multiforme market growth.

Glioblastoma Multiforme Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential Glioblastoma Multiforme drugs recently launched in the Glioblastoma market or expected to be launched during the study period. The analysis covers the Glioblastoma Multiforme market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Glioblastoma Multiforme drugs based on their sale and market share.

Scope of the Glioblastoma Multiforme Market Report
• Coverage- 7MM
• Glioblastoma Multiforme Companies- Genentech, Merck, Daiichi Sankyo, VBL Therapeutics, Diffusion Pharmaceuticals Bayer, MedImmune, DNAtrix, Chimerix, Karyopharm Therapeutics, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, Treovir, Istari Oncology, and others.
• Glioblastoma Multiforme Pipeline Therapies- Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, LAM561 (2-OHOA), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, VAL-083 (dianhydrogalactitol), MDNA55, Paxalisib (GDC-0084), Temferon, EO2401, INO-5401 + INO-9012 + LIBTAYO (cemiplimab), Delytact (Teserpaturev/DS-1647), TAFINLAR + MEKINIST, VBI-1901, and others.
• Glioblastoma Multiforme Market Dynamics: Glioblastoma Multiforme Market Drivers and Barriers

Discover more about Glioblastoma Multiforme Drugs in development @ Glioblastoma Multiforme Ongoing Clinical Trials Analysis

Table of Content
1. Key Insights
2. Glioblastoma Multiforme Market Overview at a Glance
3. Executive Summary of Glioblastoma Multiforme (GBM)
4. Key Events
5. SWOT Analysis
6. Disease Background and Overview: Glioblastoma Multiforme (GBM)
7. Treatment
8. Treatment Algorithm
9. The American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma
10. The National Comprehensive Cancer Network (NCCN) Guidelines for Glioblastoma
11. Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions
12. SEOM (Medical Oncology Spanish Society) Clinical Guidelines for Diagnosis and Treatment of Glioblastoma
13. Epidemiology and Patient Population
14. Country-wise Epidemiology of Glioblastoma Multiforme
15. Recognized Establishments
16. Patient Journey
17. Marketed Drugs
18. Emerging Drugs
19. Potential of Current Therapies and Emerging Therapies
20. Glioblastoma Multiforme: Seven Major Market Analysis
21. KOL Views
22. Market Drivers
23. Market Barriers
24. Unmet Needs
25. Market Access and Reimbursement
26. Appendix
27. DelveInsight Capabilities
28. Disclaimer
29. About DelveInsight

Yash Bhardwaj
DelveInsight
+91 96502 13330
ybhardwaj@delveinsight.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.